{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:18:40Z","timestamp":1791357520169,"version":"4.3.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R21DA045950"],"award-info":[{"award-number":["R21DA045950"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA045055"],"award-info":[{"award-number":["R01DA045055"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P50DA046351"],"award-info":[{"award-number":["P50DA046351"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CE02999"],"award-info":[{"award-number":["R01CE02999"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s11606-020-06577-5","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T02:57:39Z","timestamp":1613703459000},"page":"2952-2957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Individual and Community Factors Associated with Naloxone Co-prescribing Among Long-term Opioid Patients: a Retrospective Analysis"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1544-458X","authenticated-orcid":false,"given":"Bradley D.","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Smart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sorbero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"issue":"11","key":"6577_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","volume":"69","author":"N Wilson","year":"2020","unstructured":"Wilson N, Kariisa M, Seth P, Smith HT, Davis NL. Drug and opioid-involved overdose deaths - United States, 2017-2018. MMWR Morb Mortal Wkly Rep. 2020;69(11):290-297.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"9","key":"6577_CR2","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1007\/s11606-018-4532-5","volume":"33","author":"AJ Rose","year":"2018","unstructured":"Rose AJ, Bernson D, Chui KKH, et al. Potentially inappropriate opioid prescribing, overdose, and mortality in Massachusetts, 2011-2015. J Gen Intern Med. 2018;33(9):1512-1519.","journal-title":"J Gen Intern Med."},{"issue":"7","key":"6577_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1056\/NEJMsa1610524","volume":"376","author":"ML Barnett","year":"2017","unstructured":"Barnett ML, Olenski AR, Jena AB. Opioid-prescribing patterns of emergency physicians and risk of long-term use. N Engl J Med. 2017;376(7):663-673.","journal-title":"N Engl J Med."},{"issue":"5","key":"6577_CR4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/pds.4366","volume":"27","author":"DT Coyle","year":"2018","unstructured":"Coyle DT, Pratt CY, Ocran-Appiah J, Secora A, Kornegay C, Staffa J. Opioid analgesic dose and the risk of misuse, overdose, and death: A narrative review. Pharmacoepidemiol Drug Saf. 2018;27(5):464-472.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"6577_CR5","unstructured":"Public Policy Statement on the Use of Naloxone for the Prevention of Opioid Overdose Deaths. Chevy Chase, MD: American Society of Addiction Medicine; Undated: https:\/\/www.asam.org\/docs\/default-source\/public-policy-statements\/use-of-naloxone-for-the-prevention-of-opioid-overdose-deaths-final.pdf. Accessed May 15, 2020."},{"key":"6577_CR6","unstructured":"U.S. Health and Human Services. Naloxone: The Opioid Reversal Drug that Saves Lives. https:\/\/www.hhs.gov\/opioids\/sites\/default\/files\/2018-12\/naloxone-coprescribing-guidance.pdf. Published undated. Accessed May 11, 2020."},{"issue":"15","key":"6577_CR7","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","volume":"315","author":"D Dowell","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC Guideline for prescribing opioids for chronic pain--United States, 2016. JAMA. 2016;315(15):1624-1645.","journal-title":"JAMA."},{"issue":"2","key":"6577_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMra1202561","volume":"367","author":"EW Boyer","year":"2012","unstructured":"Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(2):146-155.","journal-title":"N Engl J Med."},{"key":"6577_CR9","doi-asserted-by":"crossref","unstructured":"Abouk R, Pacula RL, Powell D. Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose. JAMA Intern Med. 2019.","DOI":"10.1001\/jamainternmed.2019.0272"},{"issue":"5","key":"6577_CR10","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/jama.2019.7988","volume":"322","author":"CM Jones","year":"2019","unstructured":"Jones CM, Compton W, Vythilingam M, Giroir B. Naloxone co-prescribing to patients receiving prescription opioids in the Medicare Part D Program, United States, 2016-2017. JAMA. 2019;322(5):462-464.","journal-title":"JAMA."},{"key":"6577_CR11","doi-asserted-by":"crossref","unstructured":"Roberts AW. Naloxone prescribing among frequent opioid prescribers in Medicare Part D from 2013 to 2017: A retrospective study. J Gen Intern Med. 2020.","DOI":"10.1007\/s11606-020-05872-5"},{"issue":"9","key":"6577_CR12","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/add.14634","volume":"114","author":"RG Frank","year":"2019","unstructured":"Frank RG, Fry CE. The impact of expanded Medicaid eligibility on access to naloxone. Addiction. 2019;114(9):1567-1574.","journal-title":"Addiction."},{"issue":"31","key":"6577_CR13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.15585\/mmwr.mm6831e1","volume":"68","author":"GP Guy Jr","year":"2019","unstructured":"Guy GP, Jr., Haegerich TM, Evans ME, Losby JL, Young R, Jones CM. Vital Signs: Pharmacy-based naloxone dispensing - United States, 2012-2018. MMWR Morb Mortal Wkly Rep. 2019;68(31):679-686.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"6","key":"6577_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.6215","volume":"2","author":"M Sohn","year":"2019","unstructured":"Sohn M, Talbert JC, Huang Z, Lofwall MR, Freeman PR. Association of naloxone coprescription laws with naloxone prescription dispensing in the United States. JAMA Netw Open. 2019;2(6):e196215.","journal-title":"JAMA Netw Open."},{"key":"6577_CR15","doi-asserted-by":"crossref","unstructured":"Smart R, Geiger CK, Jones CM, Stein BD. An observational study of retail pharmacy naloxone prescriptions: differences across provider specialties and patient populations. J Gen Intern Med. 2019.","DOI":"10.1007\/s11606-019-05448-y"},{"key":"6577_CR16","unstructured":"IQVIA: Real World Data and Insights. https:\/\/www.iqvia.com\/solutions\/real-world-evidence\/real-world-data-and-insights. Accessed July 13, 2020."},{"key":"6577_CR17","volume-title":"2013 NCHS Urban\u2013Rural Classification Scheme for Counties; Vol 2","author":"National Center for Health Statistics","year":"2014","unstructured":"National Center for Health Statistics. 2013 NCHS Urban\u2013Rural Classification Scheme for Counties; Vol 2. Atlanta, GA: Centers for Disease Control and Prevention; 2014."},{"key":"6577_CR18","unstructured":"Centers for Disease Control Prevention. Drug Overdose Deaths. https:\/\/www.cdc.gov\/drugoverdose\/data\/statedeaths.html. Published 2020. Accessed May 20, 2020."},{"key":"6577_CR19","volume-title":"Selected housing characteristics, 2007-2011 American Community Survey 5-year estimates","author":"US Census Bureau","year":"2011","unstructured":"U.S. Census Bureau. Selected housing characteristics, 2007-2011 American Community Survey 5-year estimates. 2011."},{"key":"6577_CR20","unstructured":"U.S. Department of Health and Human Services Health Resources and Services Administration. Area Health Resources Files. 2006-2019."},{"issue":"5","key":"6577_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.3209","volume":"2","author":"S Follman","year":"2019","unstructured":"Follman S, Arora VM, Lyttle C, Moore PQ, Pho MT. Naloxone prescriptions among commercially insured Individuals at hgh risk of opioid overdose. JAMA Netw Open. 2019;2(5):e193209.","journal-title":"JAMA Netw Open."},{"key":"6577_CR22","unstructured":"Centers for Disease Control Prevention. Reported Law Enforcement Encounters Testing Positive for Fentanyl Increase Across US. https:\/\/www.cdc.gov\/drugoverdose\/data\/fentanyl-le-reports.html. Published 2016. Accessed May 20, 2020."},{"key":"6577_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.drugalcdep.2018.09.020","volume":"194","author":"A Chatterjee","year":"2019","unstructured":"Chatterjee A, Larochelle MR, Xuan Z, et al. Non-fatal opioid-related overdoses among adolescents in Massachusetts 2012-2014. Drug Alcohol Depend. 2019;194:28-31.","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"6577_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7326\/0003-4819-152-2-201001190-00006","volume":"152","author":"KM Dunn","year":"2010","unstructured":"Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med. 2010;152(2):85-92.","journal-title":"Ann Intern Med."},{"issue":"6","key":"6577_CR25","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2105\/AJPH.2020.305620","volume":"110","author":"TC Green","year":"2020","unstructured":"Green TC, Davis C, Xuan Z, Walley AY, Bratberg J. Laws mandating coprescription of naloxone and their impact on naloxone prescription in five US states, 2014-2018. Am J Public Health. 2020;110(6):881-887.","journal-title":"Am J Public Health."},{"issue":"23","key":"6577_CR26","first-page":"631","volume":"64","author":"E Wheeler","year":"2015","unstructured":"Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Opioid overdose prevention programs providing naloxone to laypersons - United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(23):631-635.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"1","key":"6577_CR27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.japh.2019.06.016","volume":"60","author":"T Thakur","year":"2020","unstructured":"Thakur T, Frey M, Chewning B. Pharmacist roles, training, and perceived barriers in naloxone dispensing: A systematic review. J Am Pharm Assoc (2003). 2020;60(1):178-194.","journal-title":"J Am Pharm Assoc (2003)."},{"issue":"1","key":"6577_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/ajad.12982","volume":"29","author":"JG Martino","year":"2020","unstructured":"Martino JG, Smith SR, Rafie S, Rafie S, Marienfeld C. Physician and pharmacist: Attitudes, facilitators, and barriers to prescribing naloxone for home rescue. Am J Addict. 2020;29(1):65-72.","journal-title":"Am J Addict."},{"issue":"8","key":"6577_CR29","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.sapharm.2019.10.015","volume":"16","author":"M Bounthavong","year":"2020","unstructured":"Bounthavong M, Suh K, Christopher MLD, Veenstra DL, Basu A, Devine EB. Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment. Res Social Adm Pharm. 2020;16(8):1033-1040.","journal-title":"Res Social Adm Pharm."},{"key":"6577_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugpo.2017.06.003","volume":"46","author":"GJ Unick","year":"2017","unstructured":"Unick GJ, Ciccarone D. US regional and demographic differences in prescription opioid and heroin-related overdose hospitalizations. Int J Drug Policy. 2017;46:112-119.","journal-title":"Int J Drug Policy."},{"issue":"1","key":"6577_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/jgs.15659","volume":"67","author":"AJ Rose","year":"2019","unstructured":"Rose AJ, McBain R, Schuler MS, et al. Effect of age on opioid prescribing, overdose, and mortality in Massachusetts, 2011 to 2015. J Am Geriatr Soc. 2019;67(1):128-132.","journal-title":"J Am Geriatr Soc."},{"key":"6577_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.drugalcdep.2018.04.020","volume":"189","author":"J Xu","year":"2018","unstructured":"Xu J, Davis CS, Cruz M, Lurie P. State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. Drug Alcohol Depend. 2018;189:37-41.","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"6577_CR33","first-page":"122","volume":"49","author":"E Behar","year":"2017","unstructured":"Behar E, Rowe C, Santos GM, Santos N, Coffin PO. Academic detailing pilot for naloxone prescribing among primary care providers in San Francisco. Fam Med. 2017;49(2):122-126.","journal-title":"Fam Med."},{"issue":"9","key":"6577_CR34","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/add.14635","volume":"114","author":"R Marino","year":"2019","unstructured":"Marino R, Landau A, Lynch M, Callaway C, Suffoletto B. Do electronic health record prompts increase take-home naloxone administration for emergency department patients after an opioid overdose? Addiction. 2019;114(9):1575-1581.","journal-title":"Addiction."},{"issue":"2S","key":"6577_CR35","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.japh.2016.11.003","volume":"57","author":"M Bounthavong","year":"2017","unstructured":"Bounthavong M, Harvey MA, Wells DL, et al. Trends in naloxone prescriptions prescribed after implementation of a National Academic Detailing Service in the Veterans Health Administration: A preliminary analysis. J Am Pharm Assoc (2003). 2017;57(2S):S68-S72.","journal-title":"J Am Pharm Assoc (2003)."},{"key":"6577_CR36","first-page":"1357633X1878209","volume":"24","author":"A Furlan","year":"2018","unstructured":"Furlan A, Zhao J, Voth J. Evaluation of an innovative tele-education intervention in chronic pain management for primary care clinicians practicing in underserved areas. J Telemed Telecare. 2018;24:1357633X18782090.","journal-title":"J Telemed Telecare."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-06577-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-020-06577-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-06577-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T01:06:59Z","timestamp":1645060019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-020-06577-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["6577"],"URL":"https:\/\/doi.org\/10.1007\/s11606-020-06577-5","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"7 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they do not have a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}